
A
Peritoneal Lavage
100
80
60
40
20
0
% CD5+ Cells
Transgenic B Cells
Non-Transgenic B Cells
VH125Tg/Vκ125SD/B6
WT/B6
VH125Tg/Vκ125SD/NOD
WT/NOD
Genotype
B
Spleen
100
80
60
40
20
0
% CD5+ Cells
Total Spleen B Cells
T1 B Cells
VH125Tg/Vκ125SD/B6
WT/B6
VH125Tg/Vκ125SD/NOD
WT/NOD
Genotype

Sup.Fig. 1

Supplemental Figure 1. VH125Tg/Vκ125^{SD} B1 cell differentiation is impaired. Peritoneal lavage or spleens were harvested from n = 6 WT/B6, n = 6 VH125Tg/Vκ125^{SD}/B6, n = 3 WT/NOD, or n = 3 VH125Tg/Vκ125^{SD}/NOD 9-13 week old male and female mice and flow cytometry was used to identify CD5^{+} B1 cells. (A) The frequency of CD5^{+} cells among transgenic (black bars, IgM^{a+}, VH125Tg/Vκ125^{SD} mice) or non-transgenic (white bars, IgM^{b+}, WT mice; IgM^{a-}, VH125Tg/Vκ125^{SD} mice) B Cells (CD19^{+} IgM^{+} live lymphocytes) was assessed in peritoneal lavage. (B) Spleens were harvested and the frequency of CD5^{+} cells among total B cells (black bars, B220^{+} IgM^{+} live lymphocytes) or T1 gated B cells (white bars, B220^{+} CD21^{low} CD23^{low} IgM$^{a\ high}$ live lymphocytes) was assessed in the indicated genotype. The average ± SD is shown.

Supplemental Table I. Number of non-insulin-binding or insulin-binding B cells following insulin autoantigen-targeted therapy of anti-insulin VH125Tg/Vκ125^{SD}/NOD mice[a]

	Immature[b, c]	T1[b, c]	T2[b, c]	Follicular[b, c]	Pre-Marginal Zone[b, c]	Marginal Zone[b, c]
Untreated, Non-Insulin-Binding	0.18 ± 0.07	18 ± 14	21 ± 6	26 ± 13	0.97 ± 0.99	33 ± 21
mAb123, Non-Insulin-Binding	0.37 ± 0.08	91 ± 15	162 ± 10	40 ± 29	6.9 ± 2.8	75 ± 29
Untreated, Insulin-Binding	7.0 ± 2.3	987 ± 776	834 ± 128	1530 ± 674	83 ± 83	3229 ± 2360
mAb123, Insulin-Binding	3.7 ± 2.1	285 ± 301	776 ± 303	4383 ± 1357	194 ± 43	977 ± 1290

[a] Spleen or bone marrow was freshly isolated 2-7 d after single i.p. injection of mAb123, n = 2 untreated mice, n = 3 mAb123-treated mice
[b] Gated as in Fig. 6B
[c] Average number of cells x 10^3 ± standard deviation. Statistical analysis was not performed.

Supplemental Table II. Number of non-insulin-binding or insulin-binding B cells following insulin autoantigen-targeted therapy of anti-insulin VH125Tg/Vκ125^{SD}/RAG2-GFP/B6 mice[a]

	Immature[b, c, d]	T1[b, c, d]	T2[b, c, d]	Follicular[b, c, d]	Pre-Marginal Zone[b, c, d]	Marginal Zone[b, c, d]
Untreated, Non-Insulin-Binding	3.3 ± 2.9	17 ± 13	67 ± 40	194 ± 139	10 ± 10	69 ± 42
mAb123, Non-Insulin-Binding	58 ± 54**	106 ± 129**	162 ± 169	139 ± 100	8.9 ± 6.9	62 ± 26
Untreated, Insulin-Binding	43 ± 24	247 ± 258	1532 ± 1123	5366 ± 3740	338 ± 256	2513 ± 1062
mAb123, Insulin-Binding	410 ± 256**	294 ± 328	242 ± 210**	3181 ± 2696	64 ± 77*	135 ± 98**

[a] Spleen or bone marrow was freshly isolated 1d after final i.p. injection of mAb123 (injected every 2 d for 1 wk), n ≥ 6 mice per group
[b] Gated as in Fig. 7A
[c] Average number of cells x 10^3 ± standard deviation
[d] ** $p < 0.01$, Mann Whitney test, two tailed, mAb123 compared to untreated

Supplemental Table III. Number of insulin-binding or non-insulin-binding B cells following short-term insulin autoantigen-targeted therapy in VH125Tg/NOD mice[a]

	Immature[b, c, d]	T1[b, c, d]	T2[b, c, d]	Follicular[b, c, d]	Marginal Zone[b, c, d]	Pancreatic Draining Lymph Nodes[b, c, d]
Untreated, Insulin-binding	3.9 ± 1.7	6.3 ± 2.7	15.4 ± 10.3	25.9 ± 12.4	21.5 ± 8.2	1.9 ± 1.7
F(ab')$_2$123, Insulin-binding	3.8 ± 1.3	5.6 ± 3.9	8.6 ± 4.7	47.5 ± 22.2	27.0 ± 12.6	1.2 ± 0.65
mAb123, Insulin-Binding	1.2 ± 0.5*	0.75 ± 0.58*	0.63 ± 0.36*	29.5 ± 15.9	6.7 ± 7.6*	0.44 ± 0.13*
Untreated, Non-Insulin-Binding	576 ± 321	593 ± 257	1615 ± 892	2526 ± 1054	1715 ± 784	94 ± 36
F(ab')$_2$123, Non-Insulin-Binding	588 ± 192	780 ± 435	1943 ± 685	3258 ± 943	2183 ± 700	104 ± 48
mAb123, Non-Insulin-Binding	498 ± 127	682 ± 164	1867 ± 668	2860 ± 1345	1797 ± 722	64 ± 12

[a] Spleen or bone marrow was freshly isolated 1-2 d after single i.p. injection of indicated therapy, n = 5 mice per group
[b] Gated as in Fig. 8B
[c] Average number of cells x 10^3 ± standard deviation
[d] * $p < 0.05$, ** $p < 0.01$, Mann Whitney test, two tailed, as compared to untreated